ASACOLON 400 Milligram Tablets Gastro-Resistant Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon 400 milligram tablets gastro-resistant

tillotts pharma limited - mesalazine - tablets gastro-resistant - 400 milligram

ASACOLON 800 Milligram Tablets Gastro-Resistant Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon 800 milligram tablets gastro-resistant

tillotts pharma limited - mesalazine - tablets gastro-resistant - 800 milligram

ASACOLON 500 Milligram Suppositories Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon 500 milligram suppositories

tillotts pharma limited - mesalazine - suppositories - 500 milligram

ASACOLON Tablets Gastro-Resistant 400 Milligram Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon tablets gastro-resistant 400 milligram

tillotts pharma limited - mesalazine - tablets gastro-resistant - 400 milligram

ASACOLON Tablets Gastro-Resistant 800 Milligram Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon tablets gastro-resistant 800 milligram

tillotts pharma limited - mesalazine - tablets gastro-resistant - 800 milligram

ASACOLON Suppositories 500 Milligram Ierland - Engels - HPRA (Health Products Regulatory Authority)

asacolon suppositories 500 milligram

tillotts pharma limited - mesalazine - suppositories - 500 milligram

Dificlir Europese Unie - Engels - EMA (European Medicines Agency)

dificlir

tillotts pharma gmbh - fidaxomicin - clostridium infections - antidiarrheals, intestinal antiinflammatory / antiinfective agents - dificlir film-coated tablets is indicated for the treatment of clostridioides difficile infections (cdi) also known as c. difficile-associated diarrhoea (cdad) in adult and paediatric patients with a body weight of at least 12.5 kg.consideration should be given to official guidelines on the appropriate use of antibacterial agents.dificlir granules for oral suspension is indicated for the treatment of clostridioides  difficile infections (cdi) also known as c. difficile-associated diarrhoea (cdad) in adults and paediatric patients from birth to < 18 years of age.consideration should be given to official guidelines on the appropriate use of antibacterial agents.